Vabysmo (Faricimab) PK Simulator
Indication: Wet age-related macular degeneration
Simulate Vabysmo (faricimab) pharmacokinetics. This PK simulator models the bispecific antibody targeting VEGF-A and Ang-2 for wet AMD and diabetic macular edema.
Drug Overview
Clinical Context
- Molecular Target
- VEGF-A/Ang-2
- Drug Class
- Bispecific mAb
- Therapeutic Area
- Ophthalmology
- Indication
- Wet age-related macular degeneration
- Route of Administration
- IVT
Model Information
- Model Type
- 2-CMT PopPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Vabysmo (Faricimab) allows you to explore concentration-time profiles under different dosing scenarios. The underlying 2-CMT PopPK model characterizes the pharmacokinetics of this bispecific mab following ivt administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Vabysmo (Faricimab) PK simulator?
This is a free, interactive pharmacokinetic simulator for Vabysmo (Faricimab) used in Wet age-related macular degeneration. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Vabysmo (Faricimab) belong to?
Vabysmo (Faricimab) is classified as a Bispecific mAb that targets VEGF-A/Ang-2. It is used in the Ophthalmology therapeutic area.
What route of administration does this model simulate?
This simulator models IVT administration of Vabysmo (Faricimab). The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a 2-CMT PopPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the Vabysmo (Faricimab) simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community